For example, it would be interesting to combine macrophage-targeting drugs (e.g., anti-CD47 or anti-CSF-1R) and T-cell immune checkpoint inhibitors (e.g., anti-PD1) to assess for synergy, as macrophage phagocytosis and subsequent antigen presentation to T-cells can augment T-cell-mediated tumor immunity [132]. The gene discussed is CD47; the disease is neoplasm.